

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Roger D. Tung, et al.

DIVISIONAL OF

SERIAL NUMBER: 09/677,382

FILING DATE: July 7, 2003

FOR: INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3  
PROTEASE

July 3, 2003  
Cambridge, Massachusetts

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants hereby make of record the documents attached on the modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. This Information Disclosure Statement is being filed:

This Information Disclosure Statement is being filed:

- within three months of the filing date of the National Application;
- within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required 37 C.F.R. §1.97.


A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). Applicants request that the Examiner consider completely the cited document during examination of this application and that the Examiner duly initial the enclosed form PTO-1449 and forward it to the undersigned with the next communication. Applicants also request that the cited documents be printed on any patent that may issue from this application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /PGO/

APPLICANTS: Tung et al.  
U.S.S.N.: Not yet assigned

The Director is hereby authorized to charge any fees that may be due in connection with this submission, or credit any overpayment to Deposit Account No. 50-0725, Reference No. VPI/98-101 CIP CON DIV US.

Respectfully submitted,

  
Lisa A. Dixon and Reg. No. 40,995  
Attorney(s) for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6396  
Fax: (617) 444-6483

Express Mail Label No.: EV 320 805 178 US

Date of Mailing: July 7, 2003

Modified Form 1449/PTO		Application Number	Not Yet Assigned
		Filing Date	July 3, 2003
		First Named Inventor	Roger D. Tung
		Group Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	VPI/98-101 CIP CON DIV US

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
B1*		DE 19648793	BASF AG	28-May-1998	
B2*		WO 96/33209	Merck Frost	24-Oct-1996	

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/677,382, filed September 29, 2000, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Peter O'Sullivan/ (08/04/2008)	Date Considered	
--------------------	---------------------------------	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

DOC ID NO: 3323